Abstract
Excess and deficient actions of FGF23 cause hypophosphatemic rickets/osteomalacia and hyperphosphatemic tumoral calcinosis, respectively. There are two kinds of assays for FGF23. Full-length assay detects only full-length FGF23 with biological activity. In contrast, C-terminal assay measures both full-length FGF23 and processed C-terminal fragment of FGF23. FGF23 measurement is useful for the diagnosis and follow-up of patients with FGF23-related hypophosphatemic diseases. In addition, full-length assay can be used for the differential diagnosis of hypophosphatemic diseases. Furthermore, many epidemiological studies indicated the association between FGF23 levels and several adverse events including higher mortality, cardiovascular diseases and progression of CKD especially in patients with CKD. Therefore, it is possible that FGF23 can be a new marker in the risk assessment of patients with CKD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
